<DOC>
	<DOC>NCT00348673</DOC>
	<brief_summary>A phase 2a study to investigate the effects of 7-day monotherapy of UK-453,061 on viral load response in asymptomatic human immunodeficiency virus (HIV) infected subjects, to assess the dose-response relationship, and to assess the pharmacokinetics (PK), safety and tolerability of UK-453,061 in asymptomatic HIV infected subjects.</brief_summary>
	<brief_title>A Study in Asymptomatic HIV Infected Patients to Investigate Pharmacodynamics, Pharmacokinetics, Safety and Toleration of UK-453,061</brief_title>
	<detailed_description />
	<criteria>Asymptomatic HIV1 infected male and patients aged 1855 years inclusive. Patients with virus not containing NNRTI resistant mutations as determined by the VircoGEN virtual phenotyping essay. Patients with a CD4 count less than 250 cells/mm3. Patients whose HIV infection has been diagnosed less than 3 months prior to screening, or for whom there is evidence of recent seroconversion. Patients with an HIV viral load less than 5000 copies/ml using RTPCR(Roche Amplicor v1.5).</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>